September is Blood Cancer Awareness Month, an opportunity for us to reaffirm our commitment to developing transformative medicines for those living with blood cancer. This year, we’re proud to partner with @Lymphoma to raise awareness. Learn more here. #BCAM
2023 was a landmark year for our company with significant global growth, data and regulatory milestones and pipeline progress in support of our broader mission to help patients around the world. Learn more about the success and impact we’re having: bit.ly/3JFD59y
Blood cancer affects millions of people across the globe. BeiGene is committed to improving outcomes for patients by creating impactful medicines that change lives. Learn more about why we do what we do. #BloodCancerAwarenessMonth
Approximately 77,000 people are diagnosed with non-Hodgkin’s lymphoma each year. We’re relentless in our mission to deliver affordable, accessible treatments that will improve patient lives affected by devastating diseases like NHL. #NHL#lymphoma#lymsm
We’re committed to evaluating our BTK inhibitor in a variety of b-cell malignancies with unmet treatment needs. We’re proud to share that more than 3,700 patients have been treated across these trials.
Earlier today, we announced that zanubrutinib achieved superior Progression Free Survival versus ibrutinib in a final analysis of the Phase 3 ALPINE trial in #CLL, as assessed by an independent review committee (IRC) and investigator. bit.ly/3esmA4D
In honor of Blood Cancer Awareness Month, we’re sitting down with members of the community to learn what this month means to them. Hear from Ken Johnson, who is living with chronic lymphocytic leukemia. #CLLsm#FightBloodCancer#BCAM#leuksm
Did you know – with our recent approval in Canada, our internally-developed treatments are now available in China, the U.S., Canada and UAE? Learn more about our pipeline and approach to R&D.
Christiane Langer, M.D., Head of Global Medical Affairs shared her thoughts on #ESMO23 and the importance of gathering as an #oncology community to discuss the latest developments in #cancer care.
Our Co-Founder, Chairman & CEO @JohnVOyler, who is featured among other global leaders in @MilkenInstitute's Power of Ideas series, calls continued cross-border collaboration crucial in the global fight. #PowerofIdeas
We are looking forward to discussing results from the interim analysis of the ALPINE trial and other data presented at #EHA2021 during our investor call & webcast later today at 12:00 PM ET. Visit our website to listen in. ir.beigene.com
After a cancer diagnosis, Ken enrolled in a BeiGene clinical trial with help from his care team. Hear more of Ken’s story as part of the #NaturesBuildingBlocks series produced by @BBCStoryWorks Commercial Productions and presented by @biotechintl
